Copy to clipboard 
Solenic Medical announced the publication of new peer-reviewed research demonstrating that alternating magnetic fields (AMF) significantly enhance antibiotic activity against bacterial biofilms across a broad range of pathogens and antibiotics, addressing a challenge in the treatment of metallic implant-associated infections.
The peer-reviewed research, “Alternating magnetic fields enhance anti-biofilm activity across pathogen and antibiotic space,” evaluated the impact of AMF in combination with antibiotics on biofilm-associated bacteria relevant to prosthetic joint infections (PJIs). The findings show that AMF exposure combined with antibiotics markedly reduced biofilm compared with antibiotics alone, including against both Gram-positive and Gram-negative organisms.
Notably, the findings demonstrated that the enhanced anti-biofilm effect was observed across different antibiotics and bacterial species and was not dependent on the specific metal composition of the implant surface, suggesting broad applicability across pathogen type, antibiotic class, and implant material in implant-associated infections.
In late 2025, Solenic reported the successful, FDA-authorized compassionate use of its investigational AMF technology (the Sola2 AMF Knee System). The noninvasive AMF treatment was delivered as an adjunct to surgery in a patient with a serious medical condition involving a PJI.
“This publication provides strong peer-reviewed validation of our AMF platform and its ability to enhance antibiotic activity against biofilms,” said Bart Bandy, Solenic Medical CEO. “Biofilm-associated infections remain one of the most difficult challenges in orthopedic care, and these results support the potential of AMF to address a critical unmet need by improving the efficacy of existing antimicrobial therapies rather than replacing them. This data reinforces our vision of delivering a non-invasive platform for advanced infection care that works alongside existing treatments to improve patient outcomes.”
Source: Solenic Medical, Inc.
Solenic Medical announced the publication of new peer-reviewed research demonstrating that alternating magnetic fields (AMF) significantly enhance antibiotic activity against bacterial biofilms across a broad range of pathogens and antibiotics, addressing a challenge in the treatment of metallic implant-associated infections.
The peer-reviewed...
Solenic Medical announced the publication of new peer-reviewed research demonstrating that alternating magnetic fields (AMF) significantly enhance antibiotic activity against bacterial biofilms across a broad range of pathogens and antibiotics, addressing a challenge in the treatment of metallic implant-associated infections.
The peer-reviewed research, “Alternating magnetic fields enhance anti-biofilm activity across pathogen and antibiotic space,” evaluated the impact of AMF in combination with antibiotics on biofilm-associated bacteria relevant to prosthetic joint infections (PJIs). The findings show that AMF exposure combined with antibiotics markedly reduced biofilm compared with antibiotics alone, including against both Gram-positive and Gram-negative organisms.
Notably, the findings demonstrated that the enhanced anti-biofilm effect was observed across different antibiotics and bacterial species and was not dependent on the specific metal composition of the implant surface, suggesting broad applicability across pathogen type, antibiotic class, and implant material in implant-associated infections.
In late 2025, Solenic reported the successful, FDA-authorized compassionate use of its investigational AMF technology (the Sola2 AMF Knee System). The noninvasive AMF treatment was delivered as an adjunct to surgery in a patient with a serious medical condition involving a PJI.
“This publication provides strong peer-reviewed validation of our AMF platform and its ability to enhance antibiotic activity against biofilms,” said Bart Bandy, Solenic Medical CEO. “Biofilm-associated infections remain one of the most difficult challenges in orthopedic care, and these results support the potential of AMF to address a critical unmet need by improving the efficacy of existing antimicrobial therapies rather than replacing them. This data reinforces our vision of delivering a non-invasive platform for advanced infection care that works alongside existing treatments to improve patient outcomes.”
Source: Solenic Medical, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
